Details for Patent: 10,478,439
✉ Email this page to a colleague
Which drugs does patent 10,478,439 protect, and when does it expire?
Patent 10,478,439 protects IMBRUVICA and is included in three NDAs.
Protection for IMBRUVICA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has fifty-eight patent family members in eighteen countries.
Summary for Patent: 10,478,439
Title: | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Abstract: | Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. |
Inventor(s): | Honigberg; Lee (San Francisco, CA), Loury; David J. (Incline Village, NV) |
Assignee: | Pharmacyclics LLC (Sunnyvale, CA) |
Application Number: | 15/965,114 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,478,439 |
Patent Claim Types: see list of patent claims | Use; |
Recent additions to Drugs Protected by US Patent 10,478,439
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharmacyclics Llc | IMBRUVICA | ibrutinib | SUSPENSION | 217003 | Aug 24, 2022 | RX | Yes | ⤷ Try a Trial | ⤷ Try a Trial | U-2666 | TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA | |||
Pharmacyclics Llc | IMBRUVICA | ibrutinib | SUSPENSION | 217003 | Aug 24, 2022 | RX | Yes | ⤷ Try a Trial | ⤷ Try a Trial | U-2970 | TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY | |||
Pharmacyclics Llc | IMBRUVICA | ibrutinib | SUSPENSION | 217003 | Aug 24, 2022 | RX | Yes | ⤷ Try a Trial | ⤷ Try a Trial | U-3422 | TREATMENT OF PEDIATRIC PATIENTS AGE 1 YEAR AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY | |||
Pharmacyclics Llc | IMBRUVICA | ibrutinib | SUSPENSION | 217003 | Aug 24, 2022 | RX | Yes | ⤷ Try a Trial | ⤷ Try a Trial | U-3842 | TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION | |||
Pharmacyclics Llc | IMBRUVICA | ibrutinib | SUSPENSION | 217003 | Aug 24, 2022 | RX | Yes | ⤷ Try a Trial | ⤷ Try a Trial | U-3843 | TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL) | |||
Pharmacyclics Llc | IMBRUVICA | ibrutinib | SUSPENSION | 217003 | Aug 24, 2022 | RX | Yes | ⤷ Try a Trial | ⤷ Try a Trial | U-3844 | TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL) WITH 17P DELETION | |||
Pharmacyclics Llc | IMBRUVICA | ibrutinib | SUSPENSION | 217003 | Aug 24, 2022 | RX | Yes | ⤷ Try a Trial | ⤷ Try a Trial | U-3845 | TREATMENT OF ADULT PATIENTS WITH WALDENSTROM’S MACROGLOBULINEMIA (WM) | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 10,478,439
International Family Members for US Patent 10,478,439
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2011261185 | ⤷ Try a Trial | |||
Australia | 2015275321 | ⤷ Try a Trial | |||
Australia | 2018204179 | ⤷ Try a Trial | |||
Australia | 2020202752 | ⤷ Try a Trial | |||
Australia | 2022201741 | ⤷ Try a Trial | |||
Australia | 2022201742 | ⤷ Try a Trial | |||
Australia | 2022201972 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |